Prevention and Management of Chemotherapy-Induced Polyneuropathy.

摘要: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a severe and common side effect caused by variety of antineoplastic agents. Approximately 30-40% patients treated with agents such as taxanes, vinca alkaloids, or platinum derivatives will develop CIPN. CIPN presents predominantly sensory axonal neuro(no)pathy occasional motor autonomic dysfunction exhibiting considerable variability clinical symptoms ranging from mild tingling sensation to neuropathic pain. Typical include numbness ("minus symptom"), weakness, abnormal gait well paresthesia pain ("positive symptoms"). As potentially lead long-term morbidity can even aggravate after cessation therapy, patients' quality life be tremendously affected. In view improved breast cancer survival outcomes, the late effects are an unmet need in these patients. Therefore, early detection assessment first important effectively prevent Therapeutic options for still limited, pharmacological treatment focuses primarily on reduction relief usually acutely managed dose discontinuation causative chemotherapy, compromising outcome. Currently, there no proven therapy prevention